US Tariff Plan Spurs Massive Pharma Investment Wave, Indian Generics on Notice

US President Donald Trump has announced a phased tariff framework on imported medicines, triggering a wave of investment commitments from the pharmaceutical industry. The plan keeps zero tariffs on imported generic medicines until August 1, 2028, after which they will face 100% tariffs for one year and 200% tariffs from August 1, 2029. Branded drugs already face a 100% tariff unless companies lower prices or manufacture domestically, though enforcement is delayed for firms investing in US production.

The tariff threat has prompted global drugmakers to ramp up US manufacturing capacity and, in some cases, negotiate pricing agreements. Several major companies have secured multi-year exemptions through deals with the Trump administration. The following investments and measures have been disclosed:

• Pfizer reached a deal on September 30 to invest $70 billion in US research and manufacturing, receiving a three-year exemption from pharmaceutical-targeted tariffs.
• GSK plans to invest $30 billion in US R&D and supply chain infrastructure over five years.
• Eli Lilly intends to build at least six new US plants, including a recently announced $3.5 billion facility in Pennsylvania, as part of a previously stated $27 billion expansion.
• Johnson & Johnson will raise US investments by 25% to $55 billion over four years, constructing four new plants, including sites in Wilson, North Carolina, and Holly Springs, North Carolina.
• Roche committed $50 billion over five years and an additional $550 million for diagnostics manufacturing, recently doubling its Holly Springs drug facility investment to approximately $2 billion.
• AstraZeneca will invest $50 billion on US manufacturing by 2030, with a major new drug substance facility in Virginia and expansions across five other states. The company has initiated technology transfers and inventory builds to minimize tariff impact.
• Novartis is spending $23 billion to build and expand 10 US facilities, including new radioligand therapy manufacturing in Florida. The company also reached a pricing agreement with the White House to launch new medicines at internationally comparable prices, sell select treatments through the government-backed TrumpRx.gov platform, and seek broader Medicaid discounts.
• Sanofi plans at least $20 billion in US investments through 2030. The CFO stated that existing inventory would limit near-term tariff effects.
• Biogen is adding $2 billion to its North Carolina manufacturing network, with an eighth site opening in late 2025.
• Merck has begun a $3 billion plant in Virginia and a $1 billion biologics facility in Delaware, part of an overall $70 billion US investment plan.

The phased approach on generic medicines has drawn particular attention from Indian manufacturers, who supply a large share of US generics. Industry leaders have called the proposal a wake-up call, urging diversification into other markets and greater innovation. A surgeon at Sarojini Naidu Medical College warned that tariff-induced price increases could hurt patient adherence, especially for chronic diseases. Experts also cautioned that shifting production to the US would require lengthy regulatory approvals, workforce development, and major capital outlays, making global supply chains essential for the foreseeable future.